|1.19||+0.1400||+13.33%||Vol 1.91M||1Y Perf -42.93%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||-0.01 -0.84%|
|Target Price||6.67||Analyst Rating||Strong Buy 1.00|
|Potential %||460.50||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||23.65||Earnings Rating||Strong Buy|
|Market Cap||173.89M||Earnings Date||11th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.05|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||847.48K|
|Avg. Monthly Volume||621.01K|
|Avg. Quarterly Volume||1.15M|
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) stock closed at 1.19 per share at the end of the most recent trading day (a 13.33% change compared to the prior day closing price) with a volume of 1.91M shares and market capitalization of 173.89M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Citius Pharmaceuticals Inc. CEO is Myron Z. Holubiak.
The one-year performance of Citius Pharmaceuticals Inc. stock is -42.93%, while year-to-date (YTD) performance is -22.73%. CTXR stock has a five-year performance of -59.11%. Its 52-week range is between 0.8306 and 2.35, which gives CTXR stock a 52-week price range ratio of 23.65%
Citius Pharmaceuticals Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 1.13, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -22.77%, a ROC of -23.91% and a ROE of -24.62%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Citius Pharmaceuticals Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Citius Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Citius Pharmaceuticals Inc. is Strong Buy (1), with a target price of $6.67, which is +460.50% compared to the current price. The earnings rating for Citius Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Citius Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Citius Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 29.06, ATR14 : 0.08, CCI20 : 179.45, Chaikin Money Flow : 0.09, MACD : 0.02, Money Flow Index : 73.78, ROC : 16.94, RSI : 73.98, STOCH (14,3) : 79.16, STOCH RSI : 0.43, UO : 60.11, Williams %R : -20.84), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Citius Pharmaceuticals Inc. in the last 12-months were:
Thu, 26 May 2022 18:05 GMT Citius Pharmaceuticals (CTXR) Receives a Buy from Maxim Group- TipRanks. All rights reserved.
Sat, 12 Feb 2022 12:37 GMT Analysts Offer Insights on Healthcare Companies: Citius Pharmaceuticals (CTXR) and Cybin (CYBN)- TipRanks. All rights reserved.
Wed, 05 Jan 2022 09:11 GMT Citius Pharmaceuticals (CTXR) Receives a Buy from Dawson James- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
This could take some time, please wait.